Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment

Edwards, Brenda K.; Brown, Martin L.; Wingo, Phyllis A.; Howe, Holly L.; Ward, Elizabeth; Ries, Lynn A. G.; Schrag, Deborah; Jamison, Patricia M.; Jemal, Ahmedin; Wu, Xiao Cheng; Friedman, Carol; Harlan, Linda C.; Warren, Joan L.; Anderson, Robert N.; Pickle, Linda Williams

doi:10.1093/jnci/dji289

Cited by 839 publications

(540 citation statements)

References 161 publications

Supporting

Mentioning

510

Contrasting

Unclassified

Order By: Relevance

“…A second report combined data gathered by the American Cancer Society (ACS), CDC, NCI and North American Association of Central Cancer Registries (NAACCR) (Edwards et al, 2005). This report focused on the 15 most common cancers in the US, incidence figures being derived from the NCI, CDC and NAACCR, and mortality data from the CDC.…”

Section: Incidence and Mortality Rates Of Hepatocellular Carcinoma Inmentioning

confidence: 99%

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

2006

View full text Add to dashboard Cite

Section: Incidence and Mortality Rates Of Hepatocellular Carcinoma Inmentioning

confidence: 99%

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

2006

View full text Add to dashboard Cite

“…Prostate cancer (PCA) is the second leading cause of cancer-related death in men reaching 31.5% of annual newly diagnosed cancers (Edwards et al, 2005). In order to improve the understanding of PCA induction and progression, a contemporary model should include a detailed analysis of mechanisms potentially inhibiting immune responsiveness to cancer.…”

Section: Introductionmentioning

confidence: 99%

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer

Feder-Mengus¹,

Wyler²,

Hudolin³

et al. 2008

European Journal of Cancer

View full text Add to dashboard Cite

Arginase 2, inducible-and endothelial-nitric-oxide synthase (iNOS and eNOS), indoleamine 2,3-dioxygenase (IDO) and TGF-beta, might impair immune functions in prostate cancer (PCA) patients. However, their expression was not comparatively analysed in PCA and benign prostatic hyperplasia (BPH). We evaluated the expression of these genes in PCA and BPH tissues. Seventy-six patients (42 BPH, 34 PCA) were enrolled. Arginase 2, eNOS and iNOS gene expression was similar in BPH and PCA tissues. TGF-beta1 gene expression was higher in BPH than in PCA tissues (p=0.035). IDO gene expression was more frequently detectable (p=0.00007) and quantitatively higher (p=0.00001) in PCA tissues than in BPH. IDO protein, expressed in endothelial cells from both BPH and PCA, was detectable in tumour cells in PCA showing evidence of high specific gene expression. In these patients, IDO gene expression correlated with kynurenine/tryptophan ratio in sera. Thus high expression of IDO gene is specifically detectable in PCA. 1 High expression of indoleamine 2,3-dioxygenase gene in prostate cancerChantal FEDER-MENGUS 1 * and Stephen WYLER 1 * , Tvrtko HUDOLIN 2 , Robin RUSZAT 1 , Lukas BUBENDORF 3 , Alberto CHIARUGI 4 , Maria PITTELLI 4 , Walter P. Seventy-six patients, 42 BPH and 34 PCA, were enrolled. Expression of arginase 2, eNOS and iNOS genes was similar in BPH and PCA tissues. TGF-β1 gene expression was significantly higher in BPH than in PCA tissues (p=0.035). In contrast IDO gene expression was more frequently detectable in PCA as compared to BPH (p=0.00007). Its extent was also significantly higher in PCA than in BPH (p=0.00001).Immunohistochemistry revealed IDO protein in endothelial cells from both BPH and PCA. However, in PCA showing evidence of high specific gene expression, IDO was detectable in tumor cells as well. In patients bearing these tumors, IDO gene expression correlated with kynurenine/tryptophan ratio in sera.These data indicate that while genes encoding Arginase 2, iNOS, eNOS and TGF-β immunosuppressive factors are expressed in PCA and BPH, high expression of IDO gene is only detectable in PCA.

show abstract

“…Cancer of the ovary has the worst prognosis of all gynaecological malignancies in the United States (Edwards et al, 2005) and Europe (Bray et al, 2005). Survival rate of patients with ovarian cancer has dramatically improved after introduction of platinum-based chemotherapy, but there still exist a large number of patients showing no response to the treatments.…”

mentioning

confidence: 99%

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

et al. 2006

View full text Add to dashboard Cite

A retrospective analysis was performed to evaluate the clinical characteristics and prognostic factors in the patients with clear cell carcinoma (CCC) of the ovary. After central pathological review and scanning of the medical records of nine Japanese institutions between 1992 and 2003, a total of 254 patients with CCC of the ovary were enrolled in the present study. Mean age was 52.4 years (range 23 -73 years). Tumours were 13% (33/254) stage Ia, 36% (92/254) stage Ic, 13% (33/254) stage II, 30% (80/254) stage III, and 6% (16/254) stage IV. Five-year progression-free survival and overall survival was 84 and 88% in stage I, 57 and 70% in stage II, 25 and 33% in stage III and 0 and 0% in stage IV, respectively. Retroperitoneal lymph node metastasis was observed in 9% in pT1a tumours, 7% in pT1c tumours, 13% in pT2 tumours, and 58% in pT3 tumours, respectively. There was no survival benefit according to chemotherapeutic differences in the patients who received complete surgical staging procedures and conventional chemotherapy. Peritoneal cytological status was an independent prognostic factor in stage Ic patients (P ¼ 0.03) and only residual tumour diameter was an independent prognostic factor in stage III, IV patients (P ¼ 0.02). Our results suggest that cytoreductive surgery resulting in no residual tumour only could improve the prognosis of advanced CCC patients.

show abstract

Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment

Cited by 839 publications

References 161 publications

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

Contact Info

Product

Resources

About